Yang Wen-Qiang, Yu Yan-Bing, Xu Xiao-Li, Ren Hong-Xiang, Zhang Li
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 Jul;36(7):831-834.
To observe the effect of Tongmai Jiangtang Capsule (TJC) on experimental diabetic peripheral neuropathy (DPN) rats.
Forty Wistar rats were divided into the TJC group, the mecobalamin treatment group, the model group, and the normal group according to random digit table, 10 in each group. Except rats in the normal group, DPN rat model was prepared using intraperitoneally in- jecting streptozotocin (STZ) in the rest rats. One rat in the model group died during the modeling. Different drugs were administered by gastrogavage to rats in corresponding groups from the 8th week after successful modeling. TJC (0.23 g crude drugs/mL, 10 mL/kg) was administered to rats in the TJC group by gastrogavage. Suspension of mecobalamin and normal saline (10 mL/kg, 0.05 mg/mL) was administered by gastrogavage to rats in the mecobalamin treatment group to the end of the 12th week. Meanwhile, equal volume of distilled water was administered by gastrogavage to rats in the model group and the normal group. Peripheral nerve conduction velocity was detected in each group. Gait analysis was performed. Changes of intraepidermal nerve fiber were observed by immunohistochemical assay. Pathological changes of tibial nerve tissue were observed using HE staining.
(1) Compared with the normal group, the nerve conduction velocity was slowed down; print length (PL), intermediary toe spread (ITS), and toe spread (TS) were added in the model group, with statistical difference (P <0. 01). Compared with the mod- el group, nerve conduction velocity was speeded; PL and ITS decreased in the TJC group and the mecobal- amin treatment group, with statistical difference (P <0. 01). Besides, the nerve conduction velocity was superior in the TJC group than in the mecobalamin treatment group, with statistical difference (P <0. 05). (2) Immunohistochemical results showed, the staining of intraepidermal nerve fiber was not clear and dispersedly distributed in the model group, with no nerve fiber staining in local regions. Nerve fibers were not regular in lesser amount and shallow stained in the mecobalamin treatment group, with no nerve fiber staining in local regions. Nerve fibers were not regular in lesser amount and dispersedly distributed in the TJC group. (3) HE staining showed that tibial nerve tissue was severely swollen with swollen myelin sheath in the mod- el group. It was difficult to identity myelin sheath. Vaculole degenerated in local regions. Swollen axon could be seen. Partial axons were separated and degenerated. In the mecobalamin treatment group tibial nerve tissue was edematous with swollen myelin sheath. It was difficult to identity myelin sheath. Axons were locally separated. In the JMC group tibial nerve tissue was swollen with unclear myelin sheath and swollen axons.
TJC could improve peripheral neuropathy of diabetic rats.
观察通脉降糖胶囊（TJC）对实验性糖尿病周围神经病变（DPN）大鼠的影响。
将40只Wistar大鼠按随机数字表法分为通脉降糖胶囊组、甲钴胺治疗组、模型组和正常组，每组10只。除正常组大鼠外，其余大鼠腹腔注射链脲佐菌素（STZ）制备DPN大鼠模型。模型组有1只大鼠在建模过程中死亡。成功建模后第8周开始对相应组大鼠进行灌胃给予不同药物。通脉降糖胶囊组大鼠灌胃给予通脉降糖胶囊（0.23 g生药/mL，10 mL/kg）。甲钴胺治疗组大鼠灌胃给予甲钴胺混悬液和生理盐水（10 mL/kg，0.05 mg/mL）至第12周结束。同时，模型组和正常组大鼠灌胃给予等体积蒸馏水。检测各组大鼠外周神经传导速度。进行步态分析。采用免疫组织化学法观察表皮内神经纤维的变化。用HE染色观察胫神经组织的病理变化。
（1）与正常组比较，模型组神经传导速度减慢；步长（PL）、中间趾展度（ITS）和趾展度（TS）增加，差异有统计学意义（P<0.01）。与模型组比较，通脉降糖胶囊组和甲钴胺治疗组神经传导速度加快；PL和ITS降低，差异有统计学意义（P<0.01）。此外，通脉降糖胶囊组神经传导速度优于甲钴胺治疗组，差异有统计学意义（P<0.05）。（2）免疫组织化学结果显示，模型组表皮内神经纤维染色不清，呈散在分布，局部无神经纤维染色。甲钴胺治疗组神经纤维排列不规则，数量较少，染色浅，局部无神经纤维染色。通脉降糖胶囊组神经纤维排列不规则，数量较少，呈散在分布。（3）HE染色显示，模型组胫神经组织严重肿胀，髓鞘肿胀，难以辨认髓鞘，局部有空泡变性，可见轴突肿胀，部分轴突分离、变性。甲钴胺治疗组胫神经组织水肿，髓鞘肿胀，难以辨认髓鞘，轴突局部分离。通脉降糖胶囊组胫神经组织肿胀，髓鞘不清，轴突肿胀。
通脉降糖胶囊可改善糖尿病大鼠周围神经病变。
